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Tyrosine kinase inhibitors have dramatically improved the prognosis of metastatic renal cell carcinoma (RCC).
However, it remains unknown whether treatment should be continued until progression or discontinued in patients
with good response. We present the history of a woman diagnosed with RCC in 1997, who started sorafenib in
2004, two years after the occurrence of lung and mediastinal metastases. Over the following 8 years, the sorafenib
dose was reduced at least 3 times due to toxicity and the treatment was discontinued twice upon the patient’s
decision, from May 2005 to March 2009, then from January 2011 to August 2011. The last evaluation in January
2013 showed stable disease. This case illustrates the feasibility of treatment discontinuation without negative
impact on survival, as previously shown by some authors.
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Renal cell carcinoma (RCC) represents only 3% of all
cancers but the incidence is increasing worldwide. The
poor prognosis of the disease, due to chemo-insensitivity,
was dramatically improved by tyrosine kinase inhibitors
(TKIs). First-line treatment currently consists of sunitinib
or interferon-alpha plus bevacizumab [1,2], and sorafenib
is considered as a second-line option [3,4].
TKIs have demonstrated significant benefits, with high
rates of partial response (PR) but median survival at 5 years
is less than 10%. Moreover, there is no consensus on the
strategy to be chosen in responders with regards to treat-
ment continuation or discontinuation. We report here a
major and prolonged clinical response following sorafenib
treatment in a patient with pulmonary, mediastinal and
brain metastases of clear cell RCC, still alive 14 years after
diagnosis.Case presentation
In April 1997, a 31-year-old woman was diagnosed with a
clear cell RCC, Fuhrman nuclear grade 1. After radical right
nephrectomy, the tumor was staged pT3N0M0. In 2002,
lung metastases were discovered and histologically con-
firmed. The patient received a combination of interferon* Correspondence: gravisg@ipc.unicancer.fr
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reproduction in any medium, provided the orand interleukin-2 for 2 years. She had stable disease after 6
months of this treatment. In February 2004, she relapsed
with mediastinal nodes. The patient was in the intermediate
risk group because of hypercalcemia. Other biological pa-
rameters considered as prognostic factors in the MSKCC
[5,6] and the Heng [7] risk classifications were normal
(serum hemoglobin, serum lactate deshydrogenase, neutro-
phils and platelets); Karnosfsky performance status and
time from diagnosis to treatment were also in the low-risk
category.
She was included in a phase III trial [3] and treated with
sorafenib 400 mg bid. After three weeks, the dose was re-
duced to 200 mg bid due to cutaneous toxicity, then re-
sumed at 400 mg bid. After 3 months, she had stable
disease (−23% according to RECIST criteria) and after 1
year, in February 2005, the patient was in partial response
(−33% according to RECIST criteria). This treatment was
pursued until May 2005. At this time, the patient presented
with two symptomatic brain metastases, treated by surgery
and whole-brain radiotherapy. Histology confirmed the
RCC origin. Other lesions were stable and the patient
decided to stop systemic therapy for personal reasons.
In March 2009, mediastinal and chest progression was
observed (+60% according to RECIST criteria) (Figure 1a
and b). Treatment with Sorafenib was restarted 400 mg
bid, but a new dose reduction at 200 mg bid was necessaryLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Tumor shrinkage assessed by computed tomography. (a and b) Mediastinal and chest progression without treatment in March
2009; (c and d) tumor shrinkage of 90% according to RECIST criteria in January 2011 after 10 months of Sorafenib; (e and f) stable disease in
January 2013.
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required frequent interruptions of treatment.
After six months, tumor shrinkage of 50% was ob-
served. The patient discontinued the treatment again
in January 2011 (Figure 1c and d). At this time, she
exhibited a major response (−90% according to RECIST
criteria as compared to March 2009). Three pulmonary
nodes appeared in August 2011 and the patient resumed
sorafenib 200 mg bid, with stable disease at last evalu-
ation in January 2013 (Figure 1e and f ).
Discussion
The approval of sorafenib and sunitinib opened a new era
in the treatment of advanced RCC. However, complete re-
missions are rare and only reported in retrospective stud-
ies [8,9], mostly with sunitinib, sometimes associated with
local treatment. Until recently, recommendations were to
continue targeted therapies as long as the disease does not
progress. However, all studies and case reports show a sig-
nificant toxicity, which negatively impacts the patient’squality of life. Moreover, since TKIs improve the outcome
of cancer patients, increase survival, and are thus pre-
scribed for several months or years, long-term administra-
tion could become a public health issue due to the high
cost of treatment. Thus, one of the main questions regard-
ing treatment with TKIs is whether the drug should be
stopped in the case of good response or continued until
progression.
The advantages of treatment discontinuation include
better tolerance and patient’s convenience, reduced costs
and possibly, the lack of development of resistant clones.
However, this strategy should not jeopardize the global
outcome of treatment. In the case presented above, inter-
mittent treatment was a relevant option, as it did not com-
promise prolonged survival.
Some publications also advocate discontinuation: Sadeghi
et al. published a retrospective series of 40 patients with
metastatic RCC [10] who had RECIST-defined stable dis-
ease or better on therapy, and who stopped treatment for
reasons excluding progression (toxicity in most cases). The
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was 10 months (1.4 to 27.2).
Other recent retrospective studies [8,11] demonstrated
that TKIs could be stopped in patients who had complete
response (CR). In the study published by Albiges et al. [8],
64 patients who had CR with sunitinib were identified.
Among those who achieved CR with sunitinib alone
(n = 36), 28 stopped treatment and 61% of them were still
in CR after median follow up of 255 days. In 24 patients
who experienced disease relapse, 11 were rechallenged
with the same TKI, among which 7 achieved PR and one
patient had stable disease. This study did not reveal any
factor that could help identify patients less likely to relapse
after treatment discontinuation.
In the study published by Demiselle et al. [11], five pa-
tients with CR and treatment discontinuation were iden-
tified. After one year, two of them were still in CR and
three patients had relapsed at 3, 12 and 15 months. In a
study published by Zama et al. [12], 23 mRCC patients
were rechallenged with sunitinib after disease progres-
sion; 22% achieved PR with median PFS of 7.2 months.
The PFS was significantly longer in patients who were
rechallenged after more than 6 months. Overall, these
results suggest that PFS can be prolonged after treat-
ment discontinuation in responders, while resistance to
TKI does not develop during treatment-free intervals.
The possible benefit of treatment discontinuation may be
based on the hypothesis that residual tumor cells remain
sensitive to TKIs whereas continuous treatment could
result in the development of resistant cell populations. In
vitro and in vivo studies suggest that resistance to TKIs is
reversible, since it may be the result of changes occurring
in the tumor and/or its microenvironment rather than
permanent genetic changes [13].
These findings must be confirmed in prospective studies.
A phase II trial, designed to investigate intermittent
sunitinib treatment, was presented at the ASCO meeting in
June 2013 [14]. In this study, patients who achieved tumor
regression of 10% or more after four cycles of sunitinib,
discontinued treatment until progression. Treatment was
maintained for other patients. Intermittent sunitinib was
associated with less toxicity in responders, and clinical effi-
cacy did not appear compromised. As in this study, our pa-
tient had more than 10% tumor regression after six months
of sorafenib, but this TKI was poorly tolerated and nega-
tively impacted her daily life. Intermittent therapy brought
her significant benefits with regard to quality of life, without
compromising the clinical efficacy of sorafenib, with 14
years of major response.
Conclusion
In conclusion, TKI treatment discontinuation or new mo-
dalities of administration need to be explored. At present,
the prognosis of RCC is determined by Furhman nucleargrade, MSKCC classification and more recently, the Heng
classification. But these clinical and biological markers
cannot predict which patients are more likely to benefit
from intermittent therapy. We need to improve our know-
ledge in prognostic factors of therapeutic efficiency and
biological predictive markers, which could help identify
patients at risk of relapse.
Consent
Written informed consent was obtained from the pa-
tient for the publication of this report and any accom-
panying images.
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